Objective. In real life, in a substantial proportion of gouty patients receiving urate-lowering therapy (ULT), urate levels are not maintained below the target of 6.0 mg/dl. We aimed to search for factors associated with poor control of serum uric acid (UA) levels in a large population of patients with gout receiving ULT. Methods. This cross-sectional study involved adults with gout in primary care who were receiving ULT. Demographics, gout history, comorbidities, lifestyle, clinical factors, concomitant treatments, and laboratory data were compared in well-controlled gout (serum UA ≤6.0 mg/dl) versus poorly controlled gout (serum UA >6.0 mg/dl) on univariate and multivariate analyses. Results. Among the 1,995 patients receiving ULT, only 445 (22.3%) had reached the target of 6.0 mg/dl serum UA. Such patients had a lower rate of gout flares within the previous year than patients without the target (mean AE SD 1.7 AE 1.4 versus 2.1 AE 1.4; P < 0.0001). The main factors associated with poor serum UA level control in multivariate analysis were low high-density lipoprotein cholesterol level (adjusted odds ratio [OR] 0.5 [95% confidence interval (95% CI) 0.26-0.96]; P = 0.04), high total cholesterol level (OR 1.83 [95% CI 1.29-2.60]; P = 0.0007), increased waist circumference (OR 1.55 [95% CI 1.11-2.13]; P = 0.008), and alcohol consumption (OR 1.52 [95% CI 1.15-2.00]; P = 0.003). Conclusion. Dyslipidemia, abdominal obesity, and alcohol consumption are the main factors associated with a poor response to ULT. Knowledge of these factors might help physicians identify cases of gout that may be less likely to achieve target urate level.
INTRODUCTION
Gout is one of the most frequent inflammatory arthritides in adults, and its incidence is steadily increasing (1, 2) . The disease results from chronic hyperuricemia, leading to deposition of monosodium urate crystals in joints and surrounding tissues. Poorly managed gout can result in subclinical chronic joint inflammation, with irreversible structural damages, impaired quality of life, and cardiovascular or renal comorbidities (3, 4) .
Gout is curable: the aim of management is to lower the serum uric acid (serum UA) level below the therapeutic target of 300-360 lmoles/liter (5-6 mg/dl) to dissolve monosodium urate crystals (5) . The American College of Rheumatology and European League Against Rheumatism guidelines recommend a treat-to-target strategy (6, 7) , and the current armamentarium offers a variety of uratelowering therapy (ULT) options to support this approach (8) . However, despite recommendations, gout often remains a poorly managed disease (9) , and for many patients with no or insufficient treatment, the serum UA target is not reached.
Lack of adherence to ULT (10, 11) , poor knowledge regarding the disease, and inappropriate medical care are all key modifiable factors that could explain the suboptimal management (12) (13) (14) (15) (16) . The efficacy of ULT, in particular allopurinol, is related in part to medication dosage, so an individual and gradual up-titration strategy for ULT may be essential to maintain the serum UA level below the therapeutic target (17) (18) (19) . However, many physicians are reluctant to increase the dosage of allopurinol, and 200-300 mg/day is the most often used posology (20) . Strategies such as patient education or pharmacist-based interventions are under investigation to improve gout treatment and adherence, often showing encouraging results (21) (22) (23) . Thus, therapeutic education could be a simple and promising tool in addition to ULT for a cure.
Nonpharmacologic and pharmacologic interventions are 2 inseparable components of the management of gout. Patients who are unlikely to achieve the treatment target may require more attention and tighter control and should be considered priorities for educational programs.
Few studies have searched for factors associated with targeting serum UA levels in patients with ULT. Apart from allopurinol dose, sex and confidence to keep serum UA levels under control were found to be independent variables associated with achieving the serum UA target (17, 24) . However, none of these studies investigated the impact of comorbidities, which are numerous in gouty patients (25) , on ULT outcomes. One recent study found that both normal renal function or end-stage kidney disease were negatively associated with ULT persistence over 2 years, but it did not assess the achievement of target serum UA level (26) . We undertook this crosssectional study to identify, regardless of type and dose of ULT, the factors, with a focus on comorbidities, associated with poor control of serum UA level in patients under ULT.
PATIENTS AND METHODS
This study involved patients ages ≥18 years with a diagnosis of gout by the physician in charge. It was a noninterventional cross-sectional multicenter study conducted in primary care by French rheumatologists and general practitioners (27) . For representativeness, each participating physician could not include more than 3 consecutive patients. Participating practitioners had to complete an individual case report form describing demographics, biometrics, gout history, and comorbidities for each patient. They performed a clinical examination and recorded the most recent (<1 year prior to inclusion) urate levels, fasting glycemia, and lipid, liver enzyme, and creatinine levels. Concomitant treatments (including diuretics, antihypertensive drugs, lipid-lowering agents [i.e., statins, fenofibrate], and oral antidiabetic drugs) were also reported. Gout flares were patient reported.
Obesity was defined as body mass index ≥30 kg/m². Waist circumference was considered increased at ≥94 cm for males and ≥80 cm for females. Hypertension was defined by blood pressure ≥130/85 mm Hg or current antihypertensive treatment. Coronary heart diseases included ischemic heart disease and history of myocardial infarction. Chronic kidney disease was defined as Modification of Diet in Renal Disease-derived estimated glomerular filtration rate <60 ml/minute/1.73m 2 . Excessive alcohol drinking was defined as >2 glasses per day for both sexes. Patients were considered beer consumers if they drank at least 1 glass (even alcohol-free) of beer per day. This definition was also used for sugar-sweetened soft drink consumption. Metabolic syndrome was defined according to the International Diabetes Federation criteria (28) . Hypertriglyceridemia was defined by blood triglyceride levels >150 mg/dl (29) . Hypercholesterolemia was defined by receiving lipid-lowering drugs or total cholesterol level >200 mg/dl (29) . Diabetes mellitus was defined by fasting plasma glycemia >126 mg/ dl (30) or use of antidiabetic drugs.
Patients were informed of the study before the collection of data and could refuse to enter the study. The French Comit e Consultatif de Traitement de l'Information relative a la Recherche Scientifique and the Commission Nationale Informatique et Libert es approved the study protocol.
The present analysis focused on patients who were receiving ULT at study inclusion and had a recent (<1 year prior to inclusion) serum urate level measurement while receiving ULT. Results are expressed as mean AE SD for continuous variables and as number (percentage) for categorical variables. Percentages were calculated in terms of nonmissing data. The treatment target for ULT was set at 6.0 mg/dl as recommended by current international guidelines. Characteristics of well-controlled serum UA level (≤6.0 mg/dl) and poorly-controlled serum UA level (>6.0 mg/dl) were compared by Student's t-test for continuous variables or chi-square test for categorical variables. The effect of demographics, clinical features, diet, and concomitant drugs on failure to achieve the target was assessed by univariate and bivariate (age-adjusted) logistic regression models, estimating odds ratios (ORs) and 2sided 95% confidence intervals (95% CIs). Variables significant on univariate analysis at a P value less than 0.20 were included in a multivariate model with forward stepwise selection. Goodness-of-fit was assessed by the Hosmer-Lemeshow test. Statistical analyses involved use of SAS software, version 9.1.3. A P value less than 0.05 was considered statistically significant.
RESULTS
Characteristics of the population. A total of 857 general practitioners and 92 rheumatologists recruited 2,813 patients from primary care. Among those patients, 2,018 (71.7%) took allopurinol, at a daily dosage of 100 mg (19%), 200 mg (43%), 300 mg (37.6%), and 400 mg (0.4%). Febuxostat was taken by 168 patients (6.0%). Very few patients were receiving probenecid and benzbromarone: n = 15 (0.5%) and n = 6 (0.2%), respectively. In total, 1,995 patients had serum urate level measurements while on ULT and constituted the analyzed subset.
Significance & Innovations
• In primary care, almost 80% of patients with gout who receive urate-lowering therapy fail to achieve the serum urate target of 6.0 mg/dl.
• Dyslipidemia, abdominal obesity, and alcohol consumption are independently associated with failure to achieve the target urate level.
• Knowledge of these modifiable risk factors might help improve patient care.
Factors Associated With Poor Outcomes of Urate-Lowering Therapy
Most of the patients were men (83.8%, mean AE SD age 64.1 AE 12.1 years) ( Table 1) . Mean AE SD duration of gout was 5.6 AE 6.2 years. Almost half had alcohol consumption exceeding 2 glasses per day. Prevalence of comorbidities was high, especially for traditional cardiovascular risk factors: abdominal obesity (80.1%), dyslipidemia (76.1%), and hypertension (69.8%).
Clinical and biologic features by serum UA level. Among all patients, only 445 (22.3%) had achieved the serum UA target, with urate level <6.0 mg/dl. As expected, serum UA level <6.0 mg/dl was associated with a reduced rate of patient-reported gout flares within the previous year (mean AE SD 1.7 AE 1.4 versus 2.1 AE 1.4; P < 0.0001) ( Table 2) .
Patients with poor versus adequate serum UA control were younger (mean AE SD 63.6 AE 12.0 versus 65.6 AE 12.3 years; P = 0.003) and had a shorter duration of gout (mean AE SD 5.3 AE 6.1 versus 6.4 AE 6.5 years; P = 0.001), even after adjustment for age (P = 0.009). A higher proportion were excessive drinkers or soft drink consumers: 49.4% versus 39.6% (P < 0.001) and 11.3% versus 7.2% (P = 0.02). Although the body mass index did not differ between the 2 groups, abdominal obesity and metabolic syndrome were both more frequent without than with serum UA control: 81.5% versus 75.3% (P = 0.006) and 64.1% versus 57.3% (P = 0.02). Furthermore, those patients had significantly higher levels of total cholesterol (P < 0.0001) and triglycerides (P = 0.002), and lower levels of high-density lipoprotein (HDL) cholesterol (P = 0.04). The prevalence of other cardiovascular risk factors or comorbidities, such as diabetes mellitus or hypertension, did not differ between the groups. In addition, concomitant treatments were similar, as were kidney and liver function.
Factors independently associated with a poor control of urate levels. The main factors independently associated with poor control of urate level were low HDL cholesterol level (OR 0.5 [95% CI 0.26-0.96]; P = 0.04), high total cholesterol level (OR 1.83 [95% CI 1.29-2.60]; P = 0.0007), abdominal obesity (OR 1.55 [95% CI 1.11-2.13]; P = 0.008), and alcohol consumption (OR 1.52 [95% CI 1.15-2.00]; P = 0.003) ( Table 3) . A younger age (OR 0.98 [95% CI 0.97-0.99]; P = 0.004) and elevated creatinine levels (OR 1.05 [95% CI 1.01-1.10]; P = 0.02) were also independently associated with failure to achieve the urate target level.
DISCUSSION
It is now widely agreed that the main objective for gout management is to lower the serum UA level below the therapeutic target of 6.0 or 5.0 mg/dl, depending on the severity of the disease (6, 7) . Although all international guidelines emphasize this point, our study shows that many gouty patients under ULT still show levels above this target and are thus exposed to acute and chronic complications of the disease. This finding supports other results (17, 31, 32) and confirms that gout is poorly treated. Here, we show that dyslipidemia, abdominal obesity, and alcohol consumption are significantly associated with poor response to ULT.
Except for alcohol consumption, the factors we identified as potential predictors of poor control of serum UA under ULT, dyslipidemia and abdominal obesity, are components of metabolic syndrome. Because of the cross-sectional design of our study, we cannot determine whether metabolic syndrome is a cause or a consequence of the poor control of serum UA with ULT. Unlike obesity, defined by body mass index ≥30 kg/m², abdominal obesity, defined by waist circumference, was associated with worse ULT outcome. Thus, body fat distribution may have a stronger impact on urate levels than global body weight. Wright et al (33) reported body size as an important predictor of allopurinol effectiveness, which 
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Latourte et al might explain our results, because allopurinol was by far the most frequently taken ULT in our patients. Total cholesterol level was the strongest factor independently associated with poor serum UA control under ULT in our study. This finding is consistent with previous works showing that dyslipidemia, and in particular hypercholesterolemia, could modulate the xanthine oxidase (XO) activity (34) . Indeed, increased plasma XO activity has been found in hypercholesterolemic rabbits (35) , as well as in patients with familial hypercholesterolemia (36) . In the latter, XO activity was significantly associated with lowdensity lipoprotein cholesterol levels (36) .
Recently, a study provided new insights into the links between hyperuricemia, metabolic syndrome, and obesity.
Mice deficient in the enterocyte urate transporter glucose transporter 9 showed hyperuricemia and features of metabolic syndrome, including obesity, which could be partially alleviated by allopurinol (37) . This observation reinforces the idea that hyperuricemia itself has a role in the onset of metabolic syndrome. Increased fructose intake was found to be associated with hyperuricemia and gout in prospective cohort studies (38, 39) , and obesity and triglyceride levels have been identified as potential predictors of incident hyperuricemia (40) . Conversely, a high serum UA level is an independent predictor of metabolic syndrome in adults (41) . UA is thought to be a key mediator of metabolic syndrome induced by a fructose-rich diet in rats (42) . In the mouse, UA shifts the endocrine balance of the adipose tissue toward an obesity-like proinflammatory state in vitro, and ULT improved this imbalance in an in vivo model of metabolic syndrome (43) . Altogether, these data directly link hyperuricemia to fructose-induced metabolic syndrome and underscore the essential role of dietary measures in gout management. Alcohol consumption was associated with a poor response to ULT in our study. Because of the high purine content in beer, we considered beer separately from global alcohol intake. However, unlike alcohol consumption, beer consumption was not associated with poor control of serum UA level under ULT. This finding disagrees with previous cohort data, which found beer and liquor consumption but not moderate wine intake associated with increased serum UA level (44, 45) . However, whether alcohol use is associated with lack of adherence to therapy, increased XO activity, or changes in pharmacokinetics properties of allopurinol is unclear, and the link between alcohol consumption and poor serum UA outcomes remains to be unraveled.
Other factors also associated with poor serum UA control in our study included younger age, although a weak association, which remained significant after multivariate analysis, in parallel with short gout duration on univariate analysis. Hence, achieving the treatment target may not be the pure consequence of aging: patients with longer gout duration could indeed be following ULT for a longer time probably because of an earlier diagnosis. Increased serum creatinine level was also slightly associated with a worse response to ULT after multivariate analysis, which is an expected finding given the established link between hyperuricemia and renal impairment (46) . However, the strength of this association was weak, which is consistent with a previous report suggesting that renal function has only a mild impact on ULT response in patients with gout (33) .
The main strengths of the present study are its large sample and its primary care setting. It also has several limitations. First, its cross-sectional design does not allow for drawing conclusions about the relationship between hyperuricemia and the factors we identified as potential predictors of poor serum UA control. Except for age and alcohol consumption, which raises no doubt about its causal role in increased serum UA level, the other factors can be linked to hyperuricemia in a 2-way manner, as a cause or a consequence. In this regard, further prospective studies are warranted. Despite this unclear relationship, each of these modifiable factors should be tightly controlled in gout management to improve the chances of reaching the treatment target. Furthermore, important genetic determinants of hyperuricemia (47) were not investigated here.
In our study, the proportion of patients taking ULT was substantially higher than what is expected in patients with gout (48) . This proportion might be due to a recruitment bias, since physicians who volunteered to participate in the study were likely more interested in gout management than those who did not. The lack of analysis of the type, dosage, or duration of ULT is another limitation of our study. The vast majority of patients who were included received XO inhibitors, thereby limiting the relevance of our findings to this class of drug. Additionally, most of them were taking allopurinol, the most widely prescribed ULT in the world. Consistent evidence indicates that allopurinol up-titration is an effective strategy to reach the serum UA target in poorly controlled gout (17, 18) . A significant proportion of our real-life sample of patients may have actually been undertreated, which necessitated an adjustment in ULT dosage to achieve the serum UA target. However, such patients could also be nonadherent and require educational measures to improve treatment adherence. Indeed, the 3 modifiable risk factors associated with failure to achieve target serum UA levels under ULT in our study are strongly influenced by lifestyle, and might be related to dietary indiscretion. As such, they likely reflect behavioral features associated with poor adherence to treatment and could thus partly explain the association. In the light of our results, adherence definitely remains a major area for further research.
We also cannot exclude the idea that at the time of study inclusion, some patients had not been treated for long enough to allow ULT to actually exert a full uratelowering effect. All of those issues regarding ULT would have been best addressed in a prospective study. Finally, the design of the study did not allow us to investigate whether physicians' prescription behavior (i.e., serum UA monitoring, allopurinol up-titrating strategy, and febuxostat use) could influence the results.
Here, we identified risk factors of a poor response to ULT in primary care, which strengthens the pathophysiologic link between metabolic syndrome and hyperuricemia. These findings may also help physicians identify patients with a need for a lifestyle change and educational intervention or a tighter followup to adapt ULT dosage, to achieve the treatment target.
In conclusion, we show that patients taking ULT and who remain above the serum UA target show a particular 
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Latourte et al phenotype of dyslipidemia, abdominal obesity, and alcohol consumption. These factors, especially combined, should lead physicians to monitor more carefully serum UA levels to adapt ULT and to strengthen nonpharmacologic measures. Moreover, this information could help practitioners detect the patients with the highest care needs, for priority access to educational programs.
